Ten head-to-head clinical trials — pulled from the GreenMedInfo archive — in which honey, turmeric, saffron, ginger and a handful of other kitchen staples matched or outperformed prescription medications. Each one links to the full research write-up.

By Sayer Ji | October 4, 2026

For nearly two decades, GreenMedInfo has done one thing most health publishers never bother with: we go into the National Library of Medicine and pull out the studies where researchers put a natural substance directly against a drug — same condition, same patients, same scoring — and then publish what they found.

Those studies exist. There are thousands of them. They just don’t get press releases, because nobody holds a patent on honey.

Below are ten of the most striking. Every one is a human trial. Every one is indexed in our database. And every one links to the long-form article where you can read the methodology, the numbers and the citations for yourself.

A word before we start: this is research information, not medical advice. Several of these trials are small. Some are single studies that have not been replicated. I have flagged which ones have the strongest designs. Read them, bring them to your practitioner, and decide for yourself. That is the entire point of having the archive.

1. Honey + Coffee vs. Prednisolone — Persistent Cough

 

The trial: Randomized, double-blind, 97 adults with post-infectious cough lasting more than three weeks. One group got a paste of honey and instant coffee every eight hours. One got the steroid prednisolone. One got guaifenesin (the active ingredient in Mucinex). Primary Care Respiratory Journal, 2013.

The result: Cough scores in the honey-coffee group fell from 2.9 to 0.2 — a 93% reduction. Prednisolone managed 3.0 to 2.4, about 20%. Guaifenesin did essentially nothing. The study authors’ own conclusion: “Honey plus coffee was found to be the most effective treatment modality.”

A kitchen remedy outperformed a corticosteroid by a factor of roughly fourteen — with none of the steroid’s immune-suppressing, bone-thinning, blood-sugar-wrecking side effects.

→ Read the full article: A Spoonful of Honey and Coffee Did What Prednisone Couldn’t

2. Curcumin vs. Metformin — Stopping Prediabetes Cold

 

The trial: Randomized controlled trial in Thailand, published in the American Diabetes Association’s own journal, Diabetes Care, 2012. Prediabetic patients took either a curcumin extract (from turmeric) or placebo for nine months.

The result: Zero patients in the curcumin group progressed to type 2 diabetes. In the placebo group, 16.4% did. Curcumin also improved beta-cell function and reduced insulin resistance, with only minor side effects reported.

For context: metformin, the front-line drug given to high-risk patients, reduced progression to diabetes by just 31% over three years in the landmark Diabetes Prevention Program. No pharmaceutical has ever come close to a 100% prevention rate.

→ Read the full article: 100% Diabetes Prevention Achieved Naturally

3. Berberine vs. Metformin — Type 2 Diabetes

 

The trial: 36 adults with newly diagnosed type 2 diabetes, three months, berberine versus metformin head-to-head. Metabolism, 2008.

The result: Berberine — a bitter alkaloid from goldenseal, barberry and Oregon grape — matched metformin on A1c, fasting glucose and post-meal glucose. Then it pulled ahead on lipids: by week 13, triglycerides and total cholesterol were significantly lower in the berberine group. In a second arm, 48 poorly-controlled diabetics on berberine saw A1c drop from 8.1% to 7.3% and fasting insulin fall 28%.

A later meta-analysis of 37 studies and 3,048 patients found berberine did not increase adverse events or the risk of hypoglycemia. Metformin, by contrast, carries a black-box risk of lactic acidosis.

→ Read the full article: Berberine Outshines Metformin for Diabetes

4. Saffron vs. Prozac and Lexapro — Depression, OCD, Postpartum Depression

The trials: Six separate head-to-head studies. In a 2016 double-blind trial, 30 mg/day of saffron matched 40 mg of fluoxetine for postpartum depression over six weeks. A 60-patient, 8-week trial found saffron equal to fluoxetine for OCD, with “many fewer” adverse effects. Additional trials found no difference against 60 mg fluoxetine for major depression and panic disorder.

The standout: A 2020 study of 54 patients found 15 mg of saffron produced significantly greater reductions in Hamilton Depression scores — and higher response and remission rates — than 10 mg of escitalopram (Lexapro).

A 2025 meta-analysis of eight RCTs confirmed it: saffron is as effective as SSRIs for depression, with fewer adverse events. The spice in your paella is running even with — and sometimes ahead of — the most prescribed class of psychiatric drugs on earth.

→ Read the full article: 6 Studies on Saffron Put Prozac to Shame

5. Honey vs. Dextromethorphan — Children’s Nighttime Cough

The trial: Children with upper respiratory infections were given buckwheat honey, honey-flavored dextromethorphan (the “DM” in Robitussin DM, Mucinex DM, Vicks Formula 44), or nothing before bed. Parents rated cough frequency, severity and sleep quality. Archives of Pediatrics & Adolescent Medicine, 2007.

The result: Honey scored best on every measure. Parents rated cough frequency 1.89 points better after honey, 1.39 after DM, and 0.92 with nothing. The quietly damning finding: dextromethorphan was not statistically better than no treatment on any outcome.

Even the CDC now advises honey for cough in anyone over one year old. The multi-billion-dollar cough syrup aisle has still not gotten the memo.

→ Read the full article: 5 Reasons Honey Should Be in Your Medicine Chest · Study abstract

6. Turmeric vs. Ibuprofen and Naproxen — Knee Osteoarthritis

 

The trials: A Thai study gave 367 knee osteoarthritis patients either 1,500 mg/day of turmeric extract or 1,200 mg/day of ibuprofen for four weeks. Separately, a 2022 double-blind RCT in Phytotherapy Research gave 60 patients either 500 mg naproxen twice daily or a capsule of turmeric extract, gingerols and piperine twice daily for a month.

The result: Turmeric matched ibuprofen for pain relief and function, with 96–97% patient satisfaction in both groups — but fewer gastrointestinal side effects. The turmeric-ginger-pepper formula relieved pain and inflammation on par with naproxen, with patients rating it equal or better on tolerability, and no adverse effects.

NSAIDs are linked to thousands of GI-bleed deaths a year. Turmeric has a 4,000-year safety record and over 900 documented health benefits in our database.

→ Read the full article: Spice-Based Relief for Aching Joints Beats Dangerous NSAID

7. Ginger vs. Mefenamic Acid and Ibuprofen — Menstrual Pain

 

The trials: 122 women with moderate-to-severe dysmenorrhea took either 250 mg of ginger every six hours or the NSAID mefenamic acid every eight hours, across two menstrual cycles. An earlier trial of 150 women compared 250 mg ginger four times daily against both mefenamic acid and ibuprofen for three days.

The result: Ginger reduced pain “significantly and equally” to the drug in the first trial — roughly half the women in each group went from moderate/severe to mild. In the second, the authors concluded flatly that ginger is as effective as the drugs.

The difference is what comes with it: NSAIDs raise the risk of ulcers, bleeding and cardiovascular events. Ginger raises the risk of nothing in particular.

→ Read the full article: Herbal Research Update for Women’s Health · Eight Unexpected Health Benefits of Ginger

8. Echinacea + Elderberry vs. Tamiflu — Influenza

 

The trial: Double-blind comparison of an Echinacea purpurea and elderberry blend against oseltamivir (Tamiflu), the world’s best-selling flu drug. Current Therapeutic Research, 2015.

The result: By day five, the herbal blend was already slightly ahead. By day ten, 90.1% of the herb group had recovered versus 84.8% on Tamiflu — with fewer complications and fewer side effects. Elderberry alone has repeatedly been shown to cut flu recovery from 7–8 days to 2–3.

Governments stockpiled billions of dollars of Tamiflu. A Cochrane review later found it shortened flu symptoms by about half a day. Elderberry costs twelve dollars.

→ Read the full article: What You Need to Know to Crush the Cold & Flu

9. Licorice (DGL) vs. Tagamet — Peptic Ulcers

 

The trial: Deglycyrrhizinated licorice (DGL) at 760 mg three times daily versus cimetidine (Tagamet), the first blockbuster acid-blocker, for peptic ulcer healing and relapse.

The result: DGL achieved 91% ulcer healing with an 8.2% relapse rate, versus 12.9% relapse with Tagamet. In the same research roundup, 3,000 mg/day of turmeric achieved 72% ulcer healing at eight weeks — comparable to omeprazole (Prilosec).

Acid-blockers are now linked to dementia, kidney disease, fractures and nutrient malabsorption with long-term use. Licorice root has been treating stomachs since Hippocrates.

→ Read the full article: The Mind Thieves — How 6 Common Medications Are Stealing Our Humanity

10. Colostrum vs. the Flu Shot — Influenza Prevention

 

The trial: Head-to-head comparison of oral colostrum against flu vaccination in both healthy adults and high-risk cardiovascular patients over two months. Clinical and Applied Thrombosis/Hemostasis, 2007.

The result: Healthy adults on colostrum alone averaged 0.33 flu episodes versus 1.1 in the vaccinated-only group — roughly three times more protective. Among the high-risk cardiac patients, the colostrum group had zero hospital admissions; the vaccinated group had multiple hospitalizations and one death. Flu-related costs in the colostrum group were about 30% of the vaccinated group’s. No significant side effects were reported.

Vitamin D, for the record, cut influenza A risk by 59% in children at 1,200 IU/day in a separate RCT. Neither appears in a single public health campaign.

→ Read the full article: Colostrum 3x More Effective Than Flu Vaccines

Honorable Mentions: When “Doing Something Else” Beat the Drug

Not every alternative comes in a capsule. From our long-running piece on non-pill interventions that outperformed pharmaceuticals in head-to-head trials:

• Sudarshan Kriya yoga breathing beat the antidepressant imipramine for depression (Journal of Affective Disorders, 2000).
• Acupuncture beat flunarizine for migraine prevention, with superior tolerability.
• Abdominal aromatherapy massage beat Tylenol for menstrual pain.
• Hypnosis matched Valium for anxiety during embryo transfer, with fewer side effects.
• Blue and red light therapy beat 5% benzoyl peroxide for acne, with no side effects.
• An elemental diet matched high-dose steroids for Crohn’s disease in children — and was superior for supporting their growth.

→ Read the full list: 11 Things Better than Drugs or Supplements for Healing

Why You Have Never Heard Most of This

Every study above is published in a peer-reviewed journal and sits in the National Library of Medicine. None of it is hidden. It is simply unfindable — buried in a haystack of tens of millions of papers, with no one paid to surface it, and, since 2021, no longer even filterable under PubMed’s complementary-and-alternative-medicine category, which was quietly removed.

That is why GreenMedInfo exists. We have spent seventeen years indexing this research — 1.4 million studies and counting, hand-mapped to over 16,000 substances, conditions and mechanisms — and keeping it free to search. In 2020 they tried to take it offline. It’s still here. It’s still yours.

If any of this was new to you, that is the whole problem — and the whole reason to search the archive, share this piece, and bring one of these studies to your next doctor’s appointment.

By Kamran Yeganegi | The Cradle | October 3, 2026

Saudi oil tankers are loading again at Yanbu, less than three weeks after drone strikes shut down the East–West Pipeline that supplies the Red Sea port. On 24 September, crude was reported to be flowing west again, although no ship had yet loaded a cargo.

By 29 September, trade sources and shipping data showed that loadings had resumed. The interruption and recovery have offered a costly demonstration of what an oil route around the Strait of Hormuz can, and cannot, do.

Yanbu, Ceyhan and Baniyas sit at three very different points on that spectrum.

Yanbu has a 1,200-kilometer pipeline in operation and an established export terminal. Ceyhan is already loading Iraqi crude, though current Iraqi flows are measured in hundreds of thousands–not millions–of barrels a day. Baniyas could eventually give Iraq a major Mediterranean outlet, but for now it remains a project that depends on new infrastructure and financing, political agreements, and protection across two fragile states.

The comparison begins with the oil that reaches ships during a crisis. Pipeline capacity matters only as much as the pumps, terminals, and security along the route allow.

Yanbu’s exposed lifeline

Saudi Arabia’s 1,200-kilometer East–West Pipeline has a nominal capacity of 7 million barrels per day (bpd). Before the September strikes, reported flows through the system were already below that capacity. Three pumping stations were damaged, and the shutdown halted crude loadings at Yanbu. Riyadh blamed Iraqi resistance factions; the Islamic Resistance in Iraq denied responsibility for the strike. Baghdad condemned the strike and opened an investigation.

Restarting the line on 22 September did not immediately restore exports. Crude had to reach Yanbu and replenish stocks before tankers could load. Two vessels scheduled for 23 September left without cargo, according to shipping data cited by Reuters. Loadings resumed days later, after a strike on pumping stations hundreds of kilometers inland had kept the port idle.

Yanbu was moving between 2 million and 2.65 million bpd when tankers returned. Traders expected flows to rise to 3 million to 4 million bpd, but a return to the pre-attack level of roughly 5.5 million bpd could take another month.

The voyage has become more expensive, too. Quoted war-risk premiums for Saudi-linked tankers calling at Yanbu have risen to around 3 percent of vessel value, up from below 1 percent in early July. For a $100 million tanker carrying two million barrels, a 3 percent premium adds roughly $1.50 to the cost of each barrel, before fuel or freight. Yanbu may bypass Hormuz, but insurers are charging heavily for the detour.

Yanbu still leaves Asia-bound cargoes exposed to the southern Red Sea and Bab al-Mandab. Attacks and warnings by Yemen’s Ansarallah-aligned army have made passage through those waters more costly and uncertain. Heidmar Maritime Holdings chief executive Pankaj Khanna has highlighted another problem for shipowners: the Red Sea lacks the US naval protection sometimes available around Hormuz.

Saudi Arabia has escaped one strait only to send its oil toward another. Cargoes bound for Europe can head north through the Red Sea, but Asian customers require the southern passage. That split limits how freely Riyadh can reroute shipments when risks around Bab al-Mandab rise.

Ceyhan’s southern supply problem

Ceyhan is already loading Iraqi crude, though its northern supply remains small compared with the volumes exported through the Gulf. Flows stood at roughly 200,000 bpd in mid-September, down from about 250,000 bpd before the war. Baghdad’s challenge is getting oil from its vast southern fields into that northern export system.

Iraq has begun moving southern oil north by road. A September trial sent 209 tanker trucks carrying about 38,000 barrels to Kirkuk over two days. Basra Oil Company later said around 250,000 bpd was being transported north for onward export through Ceyhan.

Truck convoys are useful during a crisis, but they cannot replace a high-capacity pipeline. The first trial averaged about 182 barrels per truck. Moving 250,000 barrels at that rate would require roughly 1,370 loaded truck trips, with vehicles returning south for the next run. Road conditions and loading points impose additional constraints. Expanding Ceyhan therefore depends less on the Turkish terminal than on a reliable south-to-north connection within Iraq.

Energy analyst Richard Bronze of Energy Aspects has warned against treating bypass infrastructure as a substitute for Hormuz altogether. “The idea that the strait will stop mattering or become worthless is pure rhetoric,” he told Arab News. For Iraq, the road to Ceyhan provides an outlet. It cannot yet carry southern crude at a scale that would loosen Baghdad’s reliance on the Gulf.

Baniyas across the war map

Baniyas is the most ambitious option because it could reshape Iraq’s export map. Iraq has approved preliminary studies comparing routes including Basra–Haditha–Kirkuk–Ceyhan and Basra–Haditha–Baniyas, with a consortium that includes Chevron, TI Capital, and Qatar’s UCC. Chatham House estimates the wider Iraq–Syria network at around $15 billion, with a proposed initial capacity of roughly 2 million bpd and construction potentially taking about four years.

Syrian officials have given a somewhat shorter timeframe. Syrian Petroleum Company chief Youssef Qablawi said in August that the Haditha–Baniyas project could take around 30 months to three years after final agreements and engineering work. Even the shorter timetable places Baniyas beyond the present shipping crisis, assuming agreements and funding are secured.

The route’s security problem is also more complex than a line drawn on a map. A pipeline from Haditha toward Syria would traverse western Iraq, including areas where ISIS cells remain a concern, before entering eastern Syria, where state authority remains uneven and armed groups continue to operate.

Chatham House noted in September that armed actors, including ISIS, have attacked oil wells and tanker trucks in eastern Syria, while Iraq’s fragmented security system leaves multiple actors capable of obstructing or extracting rents from infrastructure.

Israel’s strikes and military presence in Syria would loom over any pipeline to Baniyas. There is no evidence that Israel plans to attack the project, but a route through Syrian territory would depend on security guarantees Damascus cannot yet provide.

Baniyas itself is more functional than the word “reconstruction” sometimes suggests. Iraqi-origin fuel oil has already been trucked through Syria and handled at the terminal, demonstrating that a commercial logistics chain can operate.

The existing trade gives the project a foothold, but handling trucked fuel oil is far removed from loading 1–2 million bpd of pipeline crude. Storage, pumping systems, berths and terminal reliability would have to be scaled accordingly.

The old Kirkuk–Baniyas line was badly damaged, and the planned network may take a different route. Existing truck traffic therefore offers little indication of the cost or the construction work required to handle sustained crude flows.

Sanctions are another constraint, though less severe than under Bashar al-Assad. The EU lifted its broad economic sanctions on Syria in 2025 while retaining security-based and targeted measures, and the US rescinded Syria’s designation as a State Sponsor of Terrorism in August 2026. That lowers, but does not eliminate, banking, insurance, due-diligence and counterparty risk for a multi-billion-dollar project.

Iran’s leverage runs through Iraq

The geopolitical logic behind Iraq’s western routes is often framed as a means to reduce Iranian leverage over Hormuz. Iran’s influence in Iraq also extends through energy trade, political networks, and armed factions embedded in Iraq’s fragmented security order.

At the same time, Tehran does not treat Iraq exactly as it treats other Gulf states. Mostafa Khoshcheshm, a political commentator on Iranian television, told Al Jazeera in August that Iran viewed Iraq as a “friendly state” and had allowed some Iraqi oil tankers to pass Hormuz.

He said Baghdad had “always stood up to the United States.” His view is one Iranian reading of Baghdad’s position. An Iraqi move toward Gulf- and US-backed western export corridors would also alter the economic leverage surrounding it.

An expansion through Baniyas or Ceyhan would give Baghdad more room to negotiate export terms without severing its ties to Iran. Gulf investment would bring new transit partners and sources of capital, though it would not automatically shift Iraq’s political alignment.

The security question cuts both ways. Iran-aligned resistance factions could be a source of vulnerability if they viewed a corridor as threatening their strategic interests. ISIS remnants and local power brokers could also obstruct it, while transit-state disputes might halt flows without an attack. Yanbu’s damaged pumps are a warning about the vulnerability of a land corridor.

Iraq’s other proposed exits face obstacles of their own. Reviving the dormant Iraq Pipeline through Saudi Arabia (IPSA) would require Riyadh’s agreement and extensive repairs. The Basra–Aqaba route would have to be built across western Iraq and Jordan.

Egypt’s SUMED pipeline is already operating, but Baghdad has no direct way to feed Iraqi crude into it. For now, the southern Gulf terminals remain Iraq’s only outlet capable of handling exports at scale.

What reaches the tanker?

As of early October, Yanbu can move the largest potential volume because the pipeline and port already exist, but its 7 million bpd nameplate figure overstates the immediately exportable capacity, while Red Sea shipping costs and the Bab al-Mandab remain concerns.

Ceyhan can now load Iraqi crude, but expansion depends on resolving Iraq’s internal north–south logistics. Baniyas offers the largest geopolitical transformation, but it remains years, billions of dollars, and security agreements away from moving crude at scale.

Hormuz remains central to the region’s oil trade even as states invest in alternatives. Yanbu, Ceyhan and Baniyas each shift some exposure from the strait to pumping stations, desert corridors, insurers or transit governments. Their value will be measured by the barrels reaching ships when the Gulf route is under threat, not by the capacity listed in a project plan.